January 24, 2018 / 1:43 PM / 6 months ago

BRIEF-Intellipharmaceutics Provides Operational Update

Jan 24 (Reuters) - Intellipharmaceutics International Inc :

* INTELLIPHARMACEUTICS PROVIDES OPERATIONAL UPDATE

* INTELLIPHARMACEUTICS - COMMERCIALIZATION OPPORTUNITIES FOR CO’S PRODUCT HAVE BEEN “CHALLENGING IN U.S. DUE TO EXTREMELY COMPETITIVE COST ENVIRONMENT”

* INTELLIPHARMACEUTICS INTERNATIONAL INC - CONTINUES EFFORTS TO IDENTIFY OPPORTUNITIES OVERSEAS, INCLUDING IN CHINA

* INTELLIPHARMACEUTICS - RECENTLY HELD DISCUSSIONS IN CHINA TOWARD ESTABLISHING A PARTNERSHIP, HAS NOT ENTERED INTO ANY SUCH ARRANGEMENTS YET

* INTELLIPHARMACEUTICS - EVALUATING PARTNERS FOR PHASE III STUDIES OF REGABATIN XR, EXPECT TO BEGIN STUDIES IN H2 2018

* INTELLIPHARMACEUTICS - CONTINUES TO WORK WITH MALLINCKRODT AND PAR TO GAIN TRACTION IN U.S. FOR GENERIC SEROQUEL XR AND GENERIC FOCALIN XR

* INTELLIPHARMACEUTICS - ANTICIPATE THAT NDA FOR OXYCODONE ER ABUSE-DETERRENT PROGRAM WILL BE RESUBMITTED TO FDA IN LATE SUMMER 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below